Contrasting 180 Life Sciences (NASDAQ:ATNF) and Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ:CRBP) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

This table compares Corbus Pharmaceuticals and 180 Life Sciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	$880,000.00	222.01	-$44.60 million	($4.69)	-3.42
180 Life Sciences	N/A	N/A	-$19.93 million	N/A	N/A

180 Life Sciences has lower revenue, but higher earnings than Corbus Pharmaceuticals.

Insider & Institutional Ownership

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are held by institutional investors. 4.0% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of 180 Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Corbus Pharmaceuticals and 180 Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-42.28%	-32.92%
180 Life Sciences	N/A	-558.93%	-54.10%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Corbus Pharmaceuticals and 180 Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	0	0	8	1	3.11
180 Life Sciences	0	0	0	0	0.00

Corbus Pharmaceuticals presently has a consensus price target of $62.00, suggesting a potential upside of 286.53%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than 180 Life Sciences.

Volatility & Risk

Corbus Pharmaceuticals has a beta of 2.58, indicating that its stock price is 158% more volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.

Summary

Corbus Pharmaceuticals beats 180 Life Sciences on 10 of the 11 factors compared between the two stocks.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.